Amarin Corp Plc (AMRN)

[Sam81]

bio

Matinas BioPharma (NYSEMKT:MTNB) is up 4% premarket on increased volume on the heels of a Buy rating and $5 (434% upside) price target at BTIG Research citing the potential of next-gen omega-3 fatty acid compound MAT9001 that Matinas says is superior to Amarin's (NASDAQ:AMRN) Vascepa (icosapent ethyl) in lowering high triglycerides.

Might be true or not, need to wait till the completion of their study.
My take is that they are pumping their stock and using AMRN success.
What we, the board know, and soon the medical community will reach eventually is that the success of V in reducing cardiovascular events is not mainly due to reducing TG. Reducing TG is minimal
Having said that, just pumping the stock that MAT9001 is superior to V in reducing TG does not mean reducing cardiovascular events and V is playing in another league that Matina, a way bigger and superior league.

Just my Opinion